|Articles|October 2, 2021
Using ML, AI and RWD to Infer HCP Specialties
Author(s)IPM.ai
Pharmaceutical sales operations teams often rely on outdated or inaccurate data when prioritizing HCP targets, limiting promotional effectiveness. By applying artificial intelligence and machine learning to real world data, pharmaceutical companies can more effectively target physicians hiding in plain sight and PCPs behaving like specialists.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Eli Lilly Generates $1.5 Billion Stockpile of Orforglipron Ahead of FDA Decision
2
Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron
3
Pharm Exec's 2026 Pipeline Report: Next Frontiers in Focus
4
Bridging the Data Gap: How Digital Behavioral Insights Can Transform HCP Targeting in Specialty Care
5